ATE482952T1 - Ethanolaminsalz von n-(methoxy-5-methylpyrazin-2- yl)-2-(4-ä1,3,4-oxadiazol-2-ylüphenyl)pyridin-3 sulfonamid - Google Patents

Ethanolaminsalz von n-(methoxy-5-methylpyrazin-2- yl)-2-(4-ä1,3,4-oxadiazol-2-ylüphenyl)pyridin-3 sulfonamid

Info

Publication number
ATE482952T1
ATE482952T1 AT06755779T AT06755779T ATE482952T1 AT E482952 T1 ATE482952 T1 AT E482952T1 AT 06755779 T AT06755779 T AT 06755779T AT 06755779 T AT06755779 T AT 06755779T AT E482952 T1 ATE482952 T1 AT E482952T1
Authority
AT
Austria
Prior art keywords
pyridine
methoxy
ylüphenyl
methylpyrazine
oxadiazole
Prior art date
Application number
AT06755779T
Other languages
English (en)
Inventor
Catherine Good
Phillip John Hogan
Frank Montgomery
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE482952T1 publication Critical patent/ATE482952T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT06755779T 2005-07-19 2006-07-17 Ethanolaminsalz von n-(methoxy-5-methylpyrazin-2- yl)-2-(4-ä1,3,4-oxadiazol-2-ylüphenyl)pyridin-3 sulfonamid ATE482952T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0514743.4A GB0514743D0 (en) 2005-07-19 2005-07-19 Salt
PCT/GB2006/002654 WO2007010235A1 (en) 2005-07-19 2006-07-17 Ethanolamine salt of n- (3-methoxy-5-methylpyrazin-2yl) -2- (4- [1 , 3 , 4-0xadiaz0le-2-yl] phenyl) pyridine-3- sulphonamide

Publications (1)

Publication Number Publication Date
ATE482952T1 true ATE482952T1 (de) 2010-10-15

Family

ID=34897419

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06755779T ATE482952T1 (de) 2005-07-19 2006-07-17 Ethanolaminsalz von n-(methoxy-5-methylpyrazin-2- yl)-2-(4-ä1,3,4-oxadiazol-2-ylüphenyl)pyridin-3 sulfonamid

Country Status (22)

Country Link
US (2) US20080221124A1 (de)
EP (1) EP1904490B1 (de)
JP (1) JP5085544B2 (de)
KR (1) KR20080031042A (de)
CN (1) CN101223165B (de)
AT (1) ATE482952T1 (de)
AU (1) AU2006271420B2 (de)
CA (1) CA2615596A1 (de)
CY (1) CY1110942T1 (de)
DE (1) DE602006017220D1 (de)
DK (1) DK1904490T3 (de)
ES (1) ES2351442T3 (de)
GB (1) GB0514743D0 (de)
HR (1) HRP20100621T1 (de)
IL (1) IL188389A0 (de)
MX (1) MX2008000889A (de)
NO (1) NO20080053L (de)
PL (1) PL1904490T3 (de)
PT (1) PT1904490E (de)
SI (1) SI1904490T1 (de)
WO (1) WO2007010235A1 (de)
ZA (1) ZA200800328B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
GB0914287D0 (en) * 2009-08-14 2009-09-30 Pci Biotech As Compositions
CN102491973A (zh) * 2011-12-15 2012-06-13 南京友杰医药科技有限公司 Zd-4054的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US20020055457A1 (en) * 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
US20030092757A1 (en) * 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
ATE312096T1 (de) * 2001-12-18 2005-12-15 Neue verbindungen
GB0219660D0 (en) * 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use

Also Published As

Publication number Publication date
CN101223165A (zh) 2008-07-16
EP1904490B1 (de) 2010-09-29
DK1904490T3 (da) 2010-12-13
MX2008000889A (es) 2008-03-18
HRP20100621T1 (hr) 2010-12-31
JP2009501774A (ja) 2009-01-22
CY1110942T1 (el) 2015-06-10
US20080221124A1 (en) 2008-09-11
ZA200800328B (en) 2008-12-31
SI1904490T1 (sl) 2010-12-31
CN101223165B (zh) 2011-10-19
AU2006271420B2 (en) 2010-09-23
PL1904490T3 (pl) 2011-02-28
US20120101109A1 (en) 2012-04-26
NO20080053L (no) 2008-04-16
WO2007010235A1 (en) 2007-01-25
GB0514743D0 (en) 2005-08-24
KR20080031042A (ko) 2008-04-07
WO2007010235A8 (en) 2008-03-13
JP5085544B2 (ja) 2012-11-28
EP1904490A1 (de) 2008-04-02
IL188389A0 (en) 2008-04-13
DE602006017220D1 (de) 2010-11-11
AU2006271420A1 (en) 2007-01-25
HK1118276A1 (en) 2009-02-06
CA2615596A1 (en) 2007-01-25
ES2351442T3 (es) 2011-02-04
PT1904490E (pt) 2010-11-18

Similar Documents

Publication Publication Date Title
EA200800201A1 (ru) Кристаллические формы 4-метил-n-[3-(4-метилимидазол-1-ил)-5-трифторметилфенил]-3-(4-пиридин-3-илпиримидин-2-иламино)бензамида
NO20072058L (no) Inhibitorer av interaksjonen mellom MDM2 og P53
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
NO20053647L (no) Pyrazolopyridinderivater
NL1027811A1 (nl) Heterocyclische aminen als remmers 11- -hydroxy-steroïd-dehydrogenase type 1.
CY1114284T1 (el) Σουλφονυλοπυρρολες ως hdac αναστολεις
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
NO20070731L (no) Heterocykliske forbindelser.
CY1117615T1 (el) Ενωσεις θειαζολης σουλφοναμιδης και οξαζολης
CY1112780T1 (el) Νεα σουλφονυλοπυρρολια ως αναστολεις της ηdac
EA201100689A1 (ru) N-сульфонилпирролы и их применение в качестве ингибиторов гистондезацетилазы
ATE420879T1 (de) Indolizine als kinaseproteinhemmer
HRP20090229T1 (en) Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl] phenyl)pyridine-3-sulphonamide and a biphosphonate
DK1663989T3 (da) Krystallisk form af bis(E)-7-[4(4-fluorphenyl)-6-isopropyl-2-methyl(methylsulfonyl)aminopyrimidin-5-yl(3R,5S))-3-5-dihydroxyhept-6-ensyrecalciumsalt
CL2011003138A1 (es) N-(protegido- n-(3-metoxi-5-metilpirazon-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridino-3-sulfonamida y su proceso de preparacion.
EA201070410A1 (ru) Твердые формы (s)-этил-2-амино-3-(4-(2-амино-6-((r)-1-(4-хлор-2-(3-метил-1h-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропаноата и способы их применения
EA200601568A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
NO20082105L (no) Pyrazoloisokinolinderivater
CY1111432T1 (el) Τετραϋδροκινολινες για χρηση ως διαμορφωτες της μιτοτικης κινητικης πρωτεϊνης eg5
EA200600829A1 (ru) Новые кристаллические формы {2-[1-(3,5-бистрифторметилбензил)-5-пиридин-4-ил-1н-[1,2,3]триазол-4-ил]-пиридин-3-ил}-(2-хлорфенил)метанона
UY28344A1 (es) Nuevos compuestos
EA200801413A1 (ru) Гетероциклические сетр ингибиторы
CY1110942T1 (el) Αλας αιθανολαμινης n-(3-μεθοξυ-αιθοξυ-5-μεθυλπυραζιν-2-υλ)-2-(4-[1,3,4-οξαδιαζολο -2-υλ]φαινυλ)πυριδινο-3-σουλφοναμιδιου
EA200901504A1 (ru) Производные пиразолона, как ингибиторы pde4
NO20062629L (no) Oksazolderivater av tetrackliner

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1904490

Country of ref document: EP